Login Register Cart 0
Current Vascular Pharmacology

Current Vascular Pharmacology

Editor-in-Chief

ISSN (Print): 1570-1611
ISSN (Online): 1875-6212

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Mini-Review Article

Tumor-Associated Pericytes: Tumorigenicity and Targeting for Cancer Therapy

Author(s): Jiale Tan, Zihang Yu, Ruozheng Pi, Yan Lin, Wei Wang*, Minfeng Chen* and Xue Bai*

Volume 24, Issue 1, 2026

Published on: 19 February, 2025

Page: [3 - 19] Pages: 17

DOI: 10.2174/0115701611365339250213101338

Price: $65

Become a Editorial Board Member
Become a Reviewer
Become a Editor
Become a Section Editor

Abstract

Pericytes, also known as mural cells, are cells embedded between endothelial cells and the basement membrane of capillaries, where they orchestrate the morphological and functional homeostasis of blood vessels. Within the tumor microenvironment, pericytes interact closely with various cellular components, including tumor cells, stromal cells, and immune cells. Through these dynamic interactions, pericytes are activated and subsequently transform into tumor-associated pericytes (TPCs). The origin of TPCs varies depending on the tissue and tumor type, contributing to their phenotypic and functional heterogeneity. TPCs play pivotal roles in facilitating tumor progression, metastasis, immune evasion, and therapeutic resistance by promoting angiogenesis, engaging in reciprocal interactions with tumor cells, remodeling the extracellular matrix, and fostering an immunosuppressive microenvironment. This review synthesizes the latest significant advancements in targeted therapies against TPCs. It underscores the challenges inherent in developing effective anti-TPC therapies, which include the heterogeneity and pluripotency of TPCs, the absence of specific markers for precise TPC targeting, and the limited understanding of how current anti-tumor therapies affect TPCs and vice versa. This review furnishes a comprehensive understanding of the origins, markers, and functions of TPCs, and their interplays within the tumor microenvironment, providing prospective strategies for more effective anti-tumor therapy.

Keywords: Tumor-associated pericytes, cancer therapy, tumor microenvironment, heterogeneity, angiogenesis, immunomodulation.

« Previous Next »

Graphical Abstract

Graphical abstract illustrating key findings of the study

[1]
de Visser, K.E.; Joyce, J.A. The evolving tumor microenvironment: From cancer initiation to metastatic outgrowth. Cancer Cell, 2023, 41(3), 374-403.
[http://dx.doi.org/10.1016/j.ccell.2023.02.016] [PMID: 36917948]
[2]
Bejarano, L.; Jordāo, M.J.C.; Joyce, J.A. Therapeutic targeting of the tumor microenvironment. Cancer Discov., 2021, 11(4), 933-959.
[http://dx.doi.org/10.1158/2159-8290.CD-20-1808] [PMID: 33811125]
[3]
Jiang, Z.; Zhou, J.; Li, L. Pericytes in the tumor microenvironment. Cancer Lett., 2023, 556216074
[http://dx.doi.org/10.1016/j.canlet.2023.216074] [PMID: 36682706]
[4]
Hanahan, D. Hallmarks of cancer: New dimensions. Cancer Discov., 2022, 12(1), 31-46.
[http://dx.doi.org/10.1158/2159-8290.CD-21-1059] [PMID: 35022204]
[5]
Chung, A.S.; Lee, J.; Ferrara, N. Targeting the tumour vasculature: Insights from physiological angiogenesis. Nat. Rev. Cancer, 2010, 10(7), 505-514.
[http://dx.doi.org/10.1038/nrc2868] [PMID: 20574450]
[6]
Eelen, G.; Treps, L.; Li, X.; Carmeliet, P. Basic and therapeutic aspects of angiogenesis updated. Circ. Res., 2020, 127(2), 310-329.
[http://dx.doi.org/10.1161/CIRCRESAHA.120.316851] [PMID: 32833569]
[7]
Holm, A.; Heumann, T.; Augustin, H.G. Microvascular mural cell organotypic heterogeneity and functional plasticity. Trends Cell Biol., 2018, 28(4), 302-316.
[http://dx.doi.org/10.1016/j.tcb.2017.12.002] [PMID: 29307447]
[8]
Armulik, A.; Genové, G.; Betsholtz, C. Pericytes: Developmental, physiological, and pathological perspectives, problems, and promises. Dev. Cell, 2011, 21(2), 193-215.
[http://dx.doi.org/10.1016/j.devcel.2011.07.001] [PMID: 21839917]
[9]
Hellström, M.; Gerhardt, H.; Kalén, M. Lack of pericytes leads to endothelial hyperplasia and abnormal vascular morphogenesis. J. Cell Biol., 2001, 153(3), 543-554.
[http://dx.doi.org/10.1083/jcb.153.3.543] [PMID: 11331305]
[10]
Enge, M.; Bjarnegård, M.; Gerhardt, H. Endothelium-specific platelet-derived growth factor-B ablation mimics diabetic retinopathy. EMBO J., 2002, 21(16), 4307-4316.
[http://dx.doi.org/10.1093/emboj/cdf418] [PMID: 12169633]
[11]
Li, X.; Pan, J.; Liu, T. Novel TCF21 high pericyte subpopulation promotes colorectal cancer metastasis by remodelling perivascular matrix. Gut, 2023, 72(4), 710-721.
[http://dx.doi.org/10.1136/gutjnl-2022-327913] [PMID: 36805487]
[12]
Li, X.; Qi, Q.; Li, Y. TCAF2 in pericytes promotes colorectal cancer liver metastasis via inhibiting cold‐sensing TRPM8 channel. Adv. Sci., 2023, 10(30)2302717
[http://dx.doi.org/10.1002/advs.202302717] [PMID: 37635201]
[13]
Zhang, C.; Du, Z.; Gao, Y. Methionine secreted by tumor-associated pericytes supports cancer stem cells in clear cell renal carcinoma. Cell Metab., 2024, 36(4), 778-792.e10.
[http://dx.doi.org/10.1016/j.cmet.2024.01.018] [PMID: 38378000]
[14]
Hirz, T.; Mei, S.; Sarkar, H. Dissecting the immune suppressive human prostate tumor microenvironment via integrated single-cell and spatial transcriptomic analyses. Nat. Commun., 2023, 14(1), 663.
[http://dx.doi.org/10.1038/s41467-023-36325-2] [PMID: 36750562]
[15]
Huang, M.; Chen, M.; Qi, M. Perivascular cell‐derived extracellular vesicles stimulate colorectal cancer revascularization after withdrawal of antiangiogenic drugs. J. Extracell. Vesicles, 2021, 10(7)e12096
[http://dx.doi.org/10.1002/jev2.12096] [PMID: 34035882]
[16]
Huang, M.; Liu, M.; Huang, D. Tumor perivascular cell-derived extracellular vesicles promote angiogenesis via the Gas6/Axl pathway. Cancer Lett., 2022, 524, 131-143.
[http://dx.doi.org/10.1016/j.canlet.2021.10.023] [PMID: 34678434]
[17]
Wong, P.P.; Muñoz-Félix, J.M.; Hijazi, M. Cancer burden is controlled by mural cell-β3-Integrin regulated crosstalk with tumor cells. Cell, 2020, 181(6), 1346-1363.e21.
[http://dx.doi.org/10.1016/j.cell.2020.02.003] [PMID: 32473126]
[18]
Wang, Y.; Sun, Q.; Ye, Y. FGF-2 signaling in nasopharyngeal carcinoma modulates pericyte-macrophage crosstalk and metastasis. JCI Insight, 2022, 7(10)e157874
[http://dx.doi.org/10.1172/jci.insight.157874] [PMID: 35439170]
[19]
Hamzah, J.; Jugold, M.; Kiessling, F. Vascular normalization in Rgs5-deficient tumours promotes immune destruction. Nature, 2008, 453(7193), 410-414.
[http://dx.doi.org/10.1038/nature06868] [PMID: 18418378]
[20]
Zhang, X.N.; Yang, K.D.; Chen, C. Pericytes augment glioblastoma cell resistance to temozolomide through CCL5-CCR5 paracrine signaling. Cell Res., 2021, 31(10), 1072-1087.
[http://dx.doi.org/10.1038/s41422-021-00528-3] [PMID: 34239070]
[21]
Murgai, M.; Ju, W.; Eason, M. KLF4-dependent perivascular cell plasticity mediates pre-metastatic niche formation and metastasis. Nat. Med., 2017, 23(10), 1176-1190.
[http://dx.doi.org/10.1038/nm.4400] [PMID: 28920957]
[22]
Qi, M.; Fan, S.; Huang, M. Targeting FAPα-expressing hepatic stellate cells overcomes resistance to antiangiogenics in colorectal cancer liver metastasis models. J. Clin. Invest., 2022, 132(19)e157399
[http://dx.doi.org/10.1172/JCI157399] [PMID: 35951441]
[23]
Huang, Q.; Liu, L.; Xiao, D. CD44+ lung cancer stem cell-derived pericyte-like cells cause brain metastases through GPR124-enhanced trans-endothelial migration. Cancer Cell, 2023, 41(9), 1621-1636.e8.
[http://dx.doi.org/10.1016/j.ccell.2023.07.012] [PMID: 37595587]
[24]
Foster, K.; Sheridan, J.; Veiga-Fernandes, H. Contribution of neural crest-derived cells in the embryonic and adult thymus. J. Immunol., 2008, 180(5), 3183-3189.
[http://dx.doi.org/10.4049/jimmunol.180.5.3183] [PMID: 18292542]
[25]
Heglind, M.; Cederberg, A.; Aquino, J.; Lucas, G.; Ernfors, P.; Enerbäck, S. Lack of the central nervous system- and neural crest-expressed forkhead gene Foxs1 affects motor function and body weight. Mol. Cell. Biol., 2005, 25(13), 5616-5625.
[http://dx.doi.org/10.1128/MCB.25.13.5616-5625.2005] [PMID: 15964817]
[26]
Trost, A.; Schroedl, F.; Lange, S. Neural crest origin of retinal and choroidal pericytes. Invest. Ophthalmol. Vis. Sci., 2013, 54(13), 7910-7921.
[http://dx.doi.org/10.1167/iovs.13-12946] [PMID: 24235018]
[27]
Que, J.; Wilm, B.; Hasegawa, H.; Wang, F.; Bader, D.; Hogan, B.L.M. Mesothelium contributes to vascular smooth muscle and mesenchyme during lung development. Proc. Natl. Acad. Sci. USA, 2008, 105(43), 16626-16630.
[http://dx.doi.org/10.1073/pnas.0808649105] [PMID: 18922767]
[28]
Wilm, B.; Ipenberg, A.; Hastie, N.D.; Burch, J.B.E.; Bader, D.M. The serosal mesothelium is a major source of smooth muscle cells of the gut vasculature. Development, 2005, 132(23), 5317-5328.
[http://dx.doi.org/10.1242/dev.02141] [PMID: 16284122]
[29]
Asahina, K.; Zhou, B.; Pu, W.T.; Tsukamoto, H. Septum transversum-derived mesothelium gives rise to hepatic stellate cells and perivascular mesenchymal cells in developing mouse liver. Hepatology, 2011, 53(3), 983-995.
[http://dx.doi.org/10.1002/hep.24119] [PMID: 21294146]
[30]
Bababeygy, S.R.; Cheshier, S.H.; Hou, L.C.; Higgins, D.M.O.; Weissman, I.L.; Tse, V.C.K. Hematopoietic stem cell-derived pericytic cells in brain tumor angio-architecture. Stem Cells Dev., 2008, 17(1), 11-18.
[http://dx.doi.org/10.1089/scd.2007.0117] [PMID: 18240955]
[31]
Birbrair, A.; Zhang, T.; Wang, Z.M.; Messi, M.L.; Mintz, A.; Delbono, O. Pericytes: multitasking cells in the regeneration of injured, diseased, and aged skeletal muscle. Front. Aging Neurosci., 2014, 6, 245.
[http://dx.doi.org/10.3389/fnagi.2014.00245] [PMID: 25278877]
[32]
Hosaka, K.; Yang, Y.; Seki, T. Pericyte-fibroblast transition promotes tumor growth and metastasis. Proc. Natl. Acad. Sci. USA, 2016, 113(38), E5618-E5627.
[http://dx.doi.org/10.1073/pnas.1608384113] [PMID: 27608497]
[33]
Stratman, A.N.; Schwindt, A.E.; Malotte, K.M.; Davis, G.E. Endothelial-derived PDGF-BB and HB-EGF coordinately regulate pericyte recruitment during vasculogenic tube assembly and stabilization. Blood, 2010, 116(22), 4720-4730.
[http://dx.doi.org/10.1182/blood-2010-05-286872] [PMID: 20739660]
[34]
Yu, Y.; Leng, Y.; Song, X. Extracellular matrix stiffness regulates microvascular stability by controlling endothelial paracrine signaling to determine pericyte fate. Arterioscler. Thromb. Vasc. Biol., 2023, 43(10), 1887-1899.
[http://dx.doi.org/10.1161/ATVBAHA.123.319119] [PMID: 37650330]
[35]
Minutti, C.M.; Modak, R.V.; Macdonald, F. A macrophage-pericyte axis directs tissue restoration via amphiregulin-induced transforming growth factor beta activation. Immunity, 2019, 50(3), 645-654.e6.
[http://dx.doi.org/10.1016/j.immuni.2019.01.008] [PMID: 30770250]
[36]
Diéguez-Hurtado, R.; Kato, K.; Giaimo, B.D. Loss of the transcription factor RBPJ induces disease-promoting properties in brain pericytes. Nat. Commun., 2019, 10(1), 2817.
[http://dx.doi.org/10.1038/s41467-019-10643-w] [PMID: 31249304]
[37]
Machuca-Parra, A.I.; Bigger-Allen, A.A.; Sanchez, A.V. Therapeutic antibody targeting of Notch3 signaling prevents mural cell loss in CADASIL. J. Exp. Med., 2017, 214(8), 2271-2282.
[http://dx.doi.org/10.1084/jem.20161715] [PMID: 28698285]
[38]
Jin, S.; Hansson, E.M.; Tikka, S. Notch signaling regulates platelet-derived growth factor receptor-β expression in vascular smooth muscle cells. Circ. Res., 2008, 102(12), 1483-1491.
[http://dx.doi.org/10.1161/CIRCRESAHA.107.167965] [PMID: 18483410]
[39]
van Splunder, H.; Villacampa, P.; Martínez-Romero, A.; Graupera, M. Pericytes in the disease spotlight. Trends Cell Biol., 2024, 34(1), 58-71.
[http://dx.doi.org/10.1016/j.tcb.2023.06.001] [PMID: 37474376]
[40]
Meng, Y.M.; Jiang, X.; Zhao, X. Hexokinase 2-driven glycolysis in pericytes activates their contractility leading to tumor blood vessel abnormalities. Nat. Commun., 2021, 12(1), 6011.
[http://dx.doi.org/10.1038/s41467-021-26259-y] [PMID: 34650057]
[41]
Kuppe, C.; Ibrahim, M.M.; Kranz, J. Decoding myofibroblast origins in human kidney fibrosis. Nature, 2021, 589(7841), 281-286.
[http://dx.doi.org/10.1038/s41586-020-2941-1] [PMID: 33176333]
[42]
Yang, A.C.; Vest, R.T.; Kern, F. A human brain vascular atlas reveals diverse mediators of Alzheimer’s risk. Nature, 2022, 603(7903), 885-892.
[http://dx.doi.org/10.1038/s41586-021-04369-3] [PMID: 35165441]
[43]
Vanlandewijck, M.; He, L.; Mäe, M.A. A molecular atlas of cell types and zonation in the brain vasculature. Nature, 2018, 554(7693), 475-480.
[http://dx.doi.org/10.1038/nature25739] [PMID: 29443965]
[44]
Muhl, L.; Genové, G.; Leptidis, S. Single-cell analysis uncovers fibroblast heterogeneity and criteria for fibroblast and mural cell identification and discrimination. Nat. Commun., 2020, 11(1), 3953.
[http://dx.doi.org/10.1038/s41467-020-17740-1] [PMID: 32769974]
[45]
Muhl, L.; Mocci, G.; Pietilä, R. A single-cell transcriptomic inventory of murine smooth muscle cells. Dev. Cell, 2022, 57(20), 2426-2443.e6.
[http://dx.doi.org/10.1016/j.devcel.2022.09.015] [PMID: 36283392]
[46]
Shih, Y.H.; Portman, D.; Idrizi, F.; Grosse, A.; Lawson, N.D. Integrated molecular analysis identifies a conserved pericyte gene signature in zebrafish. Development, 2021, 148(23)dev200189
[http://dx.doi.org/10.1242/dev.200189] [PMID: 34751773]
[47]
Glabman, R.A.; Choyke, P.L.; Sato, N. Cancer-associated fibroblasts: Tumorigenicity and targeting for cancer therapy. Cancers, 2022, 14(16), 3906.
[http://dx.doi.org/10.3390/cancers14163906] [PMID: 36010899]
[48]
Du, Y.; Shi, J.; Wang, J. Integration of pan-cancer single-cell and spatial transcriptomics reveals stromal cell features and therapeutic targets in tumor microenvironment. Cancer Res., 2024, 84(2), 192-210.
[http://dx.doi.org/10.1158/0008-5472.CAN-23-1418] [PMID: 38225927]
[49]
Sziraki, A.; Zhong, Y.; Neltner, A.M. A high‐throughput single‐cell RNA expression profiling method identifies human pericyte markers. Neuropathol. Appl. Neurobiol., 2023, 49(6)e12942
[http://dx.doi.org/10.1111/nan.12942] [PMID: 37812061]
[50]
Crisan, M.; Yap, S.; Casteilla, L. A perivascular origin for mesenchymal stem cells in multiple human organs. Cell Stem Cell, 2008, 3(3), 301-313.
[http://dx.doi.org/10.1016/j.stem.2008.07.003] [PMID: 18786417]
[51]
Ozerdem, U.; Grako, K.A.; Dahlin-Huppe, K.; Monosov, E.; Stallcup, W.B. NG2 proteoglycan is expressed exclusively by mural cells during vascular morphogenesis. Dev. Dyn., 2001, 222(2), 218-227.
[http://dx.doi.org/10.1002/dvdy.1200] [PMID: 11668599]
[52]
Liu, Y.; Guo, J.; Matoga, M.; Korotkova, M.; Jakobsson, P.J.; Aguzzi, A. NG2 glia protect against prion neurotoxicity by inhibiting microglia-to-neuron prostaglandin E2 signaling. Nat. Neurosci., 2024, 27(8), 1534-1544.
[http://dx.doi.org/10.1038/s41593-024-01663-x] [PMID: 38802591]
[53]
Smyth, L.C.D.; Rustenhoven, J.; Scotter, E.L. Markers for human brain pericytes and smooth muscle cells. J. Chem. Neuroanat., 2018, 92, 48-60.
[http://dx.doi.org/10.1016/j.jchemneu.2018.06.001] [PMID: 29885791]
[54]
Zhu, S.; Chen, M.; Ying, Y. Versatile subtypes of pericytes and their roles in spinal cord injury repair, bone development and repair. Bone Res., 2022, 10(1), 30.
[http://dx.doi.org/10.1038/s41413-022-00203-2] [PMID: 35296645]
[55]
Zimmerlin, L.; Donnenberg, V.S.; Rubin, J.P.; Donnenberg, A.D. Mesenchymal markers on human adipose stem/progenitor cells. Cytometry A, 2013, 83A(1), 134-140.
[http://dx.doi.org/10.1002/cyto.a.22227] [PMID: 23184564]
[56]
Xing, S.; Luo, Y.; Liu, Z. Targeting endothelial CD146 attenuates colitis and prevents colitis-associated carcinogenesis. Am. J. Pathol., 2014, 184(5), 1604-1616.
[http://dx.doi.org/10.1016/j.ajpath.2014.01.031] [PMID: 24767106]
[57]
Dagur, P.K.; McCoy, J.P., Jr Endothelial-binding, proinflammatory T cells identified by MCAM (CD146) expression: Characterization and role in human autoimmune diseases. Autoimmun. Rev., 2015, 14(5), 415-422.
[http://dx.doi.org/10.1016/j.autrev.2015.01.003] [PMID: 25595133]
[58]
Zhang, H.; Bryson, V.G.; Wang, C. Desmin interacts with STIM1 and coordinates Ca2+ signaling in skeletal muscle. JCI Insight, 2021, 6(17)e143472
[http://dx.doi.org/10.1172/jci.insight.143472] [PMID: 34494555]
[59]
Hong, C.L.; Yu, I.S.; Pai, C.H. CD248 regulates Wnt signaling in pericytes to promote angiogenesis and tumor growth in lung cancer. Cancer Res., 2022, 82(20), 3734-3750.
[http://dx.doi.org/10.1158/0008-5472.CAN-22-1695] [PMID: 35950912]
[60]
Ash, S.L.; Orha, R.; Mole, H. Targeting the activated microenvironment with endosialin (CD248)-directed CAR-T cells ablates perivascular cells to impair tumor growth and metastasis. J. Immunother. Cancer, 2024, 12(2)e008608
[http://dx.doi.org/10.1136/jitc-2023-008608] [PMID: 38413223]
[61]
Kim, H.S.; Choi, D.Y.; Yun, S.J. Proteomic analysis of microvesicles derived from human mesenchymal stem cells. J. Proteome Res., 2012, 11(2), 839-849.
[http://dx.doi.org/10.1021/pr200682z] [PMID: 22148876]
[62]
Kontsekova, S.; Polcicova, K.; Takacova, M.; Pastorekova, S. Molecular and functional links to tumor Angiogenesis. Neoplasma, 2016, 63(2), 183-192.
[http://dx.doi.org/10.4149/202_15090N474]
[63]
Cho, H.; Kozasa, T.; Bondjers, C.; Betsholtz, C.; Kehrl, J.H. Pericyte‐specific expression of Rgs5: implications for PDGF and EDG receptor signaling during vascular maturation. FASEB J., 2003, 17(3), 1-17.
[http://dx.doi.org/10.1096/fj.02-0340fje] [PMID: 12514120]
[64]
Kong, P.; Wang, X.; Gao, Y.K. RGS5 maintaining vascular homeostasis is altered by the tumor microenvironment. Biol. Direct, 2023, 18(1), 78.
[http://dx.doi.org/10.1186/s13062-023-00437-y] [PMID: 37986113]
[65]
Song, S.; Ewald, A.J.; Stallcup, W.; Werb, Z.; Bergers, G. PDGFRβ+ perivascular progenitor cells in tumours regulate pericyte differentiation and vascular survival. Nat. Cell Biol., 2005, 7(9), 870-879.
[http://dx.doi.org/10.1038/ncb1288] [PMID: 16113679]
[66]
Costa, A.; Kieffer, Y.; Scholer-Dahirel, A. Fibroblast heterogeneity and immunosuppressive environment in human breast cancer. Cancer Cell, 2018, 33(3), 463-479.e10.
[http://dx.doi.org/10.1016/j.ccell.2018.01.011] [PMID: 29455927]
[67]
Nurmik, M.; Ullmann, P.; Rodriguez, F.; Haan, S.; Letellier, E. In search of definitions: Cancer‐associated fibroblasts and their markers. Int. J. Cancer, 2020, 146(4), 895-905.
[http://dx.doi.org/10.1002/ijc.32193] [PMID: 30734283]
[68]
Sugimoto, H.; Mundel, T.M.; Kieran, M.W.; Kalluri, R. Identification of fibroblast heterogeneity in the tumor microenvironment. Cancer Biol. Ther., 2006, 5(12), 1640-1646.
[http://dx.doi.org/10.4161/cbt.5.12.3354] [PMID: 17106243]
[69]
Dar, A.; Domev, H.; Ben-Yosef, O. Multipotent vasculogenic pericytes from human pluripotent stem cells promote recovery of murine ischemic limb. Circulation, 2012, 125(1), 87-99.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.111.048264] [PMID: 22095829]
[70]
Mesa-Ciller, C.; Turiel, G.; Guajardo-Grence, A. Unique expression of the atypical mitochondrial subunit NDUFA4L2 in cerebral pericytes fine tunes HIF activity in response to hypoxia. J. Cereb. Blood Flow Metab., 2023, 43(1), 44-58.
[http://dx.doi.org/10.1177/0271678X221118236] [PMID: 35929074]
[71]
Cords, L.; Tietscher, S.; Anzeneder, T. Cancer-associated fibroblast classification in single-cell and spatial proteomics data. Nat. Commun., 2023, 14(1), 4294.
[http://dx.doi.org/10.1038/s41467-023-39762-1] [PMID: 37463917]
[72]
Chen, Z.; Wei, X.; Wang, X. NDUFA4L2 promotes glioblastoma progression, is associated with poor survival, and can be effectively targeted by apatinib. Cell Death Dis., 2021, 12(4), 377.
[http://dx.doi.org/10.1038/s41419-021-03646-3] [PMID: 33828084]
[73]
Ji, H.; Li, Y.; Sun, H. Decoding the cell atlas and inflammatory features of human intracranial Aneurysm wall by single‐cell RNA sequencing. J. Am. Heart Assoc., 2024, 13(5)e032456
[http://dx.doi.org/10.1161/JAHA.123.032456] [PMID: 38390814]
[74]
Wang, S.; Zhang, S.; Li, X. HIGD1B, as a novel prognostic biomarker, is involved in regulating the tumor microenvironment and immune cell infiltration; its overexpression leads to poor prognosis in gastric cancer patients. Front. Immunol., 2024, 151415148
[http://dx.doi.org/10.3389/fimmu.2024.1415148] [PMID: 39108265]
[75]
Ando, K.; Tong, L.; Peng, D. KCNJ8/ABCC9-containing K-ATP channel modulates brain vascular smooth muscle development and neurovascular coupling. Dev. Cell, 2022, 57(11), 1383-1399.e7.
[http://dx.doi.org/10.1016/j.devcel.2022.04.019] [PMID: 35588738]
[76]
Pan, X.; Li, X.; Dong, L. Tumour vasculature at single-cell resolution. Nature, 2024, 632(8024), 429-436.
[http://dx.doi.org/10.1038/s41586-024-07698-1] [PMID: 38987599]
[77]
Hoogstrate, Y.; Draaisma, K.; Ghisai, S.A. Transcriptome analysis reveals tumor microenvironment changes in glioblastoma. Cancer Cell, 2023, 41(4), 678-692.e7.
[http://dx.doi.org/10.1016/j.ccell.2023.02.019] [PMID: 36898379]
[78]
Teuwen, L.A.; De Rooij, L.P.M.H.; Cuypers, A. Tumor vessel co-option probed by single-cell analysis. Cell Rep., 2021, 35(11)109253
[http://dx.doi.org/10.1016/j.celrep.2021.109253] [PMID: 34133923]
[79]
Feng, F.; Feng, X.; Zhang, D.; Li, Q.; Yao, L. Matrix stiffness induces pericyte-fibroblast transition through YAP activation. Front. Pharmacol., 2021, 12698275
[http://dx.doi.org/10.3389/fphar.2021.698275] [PMID: 34135765]
[80]
Ferland-McCollough, D.; Slater, S.; Richard, J.; Reni, C.; Mangialardi, G. Pericytes, an overlooked player in vascular pathobiology. Pharmacol. Ther., 2017, 171, 30-42.
[http://dx.doi.org/10.1016/j.pharmthera.2016.11.008] [PMID: 27916653]
[81]
Perrot, C.Y.; Herrera, J.L.; Fournier-Goss, A.E.; Komatsu, M. Prostaglandin E2 breaks down pericyte-endothelial cell interaction via EP1 and EP4-dependent downregulation of pericyte N-cadherin, connexin-43, and R-Ras. Sci. Rep., 2020, 10(1), 11186.
[http://dx.doi.org/10.1038/s41598-020-68019-w] [PMID: 32636414]
[82]
Zhang, X.; Ren, L.; Wu, J. ARHGEF37 overexpression promotes extravasation and metastasis of hepatocellular carcinoma via directly activating Cdc42. J. Exp. Clin. Cancer Res., 2022, 41(1), 230.
[http://dx.doi.org/10.1186/s13046-022-02441-y] [PMID: 35869555]
[83]
Kemp, S.S.; Aguera, K.N.; Cha, B.; Davis, G.E. Defining endothelial cell-derived factors that promote pericyte recruitment and capillary network assembly. Arterioscler. Thromb. Vasc. Biol., 2020, 40(11), 2632-2648.
[http://dx.doi.org/10.1161/ATVBAHA.120.314948] [PMID: 32814441]
[84]
Dubrac, A.; Künzel, S.E.; Künzel, S.H. NCK-dependent pericyte migration promotes pathological neovascularization in ischemic retinopathy. Nat. Commun., 2018, 9(1), 3463.
[http://dx.doi.org/10.1038/s41467-018-05926-7] [PMID: 30150707]
[85]
Darland, D.C.; Massingham, L.J.; Smith, S.R.; Piek, E.; Saint-Geniez, M.; D’Amore, P.A. Pericyte production of cell-associated VEGF is differentiation-dependent and is associated with endothelial survival. Dev. Biol., 2003, 264(1), 275-288.
[http://dx.doi.org/10.1016/j.ydbio.2003.08.015] [PMID: 14623248]
[86]
Ichikawa, K.; Watanabe Miyano, S.; Minoshima, Y.; Matsui, J.; Funahashi, Y. Activated FGF2 signaling pathway in tumor vasculature is essential for acquired resistance to anti-VEGF therapy. Sci. Rep., 2020, 10(1), 2939.
[http://dx.doi.org/10.1038/s41598-020-59853-z] [PMID: 32076044]
[87]
Franco, M.; Roswall, P.; Cortez, E.; Hanahan, D.; Pietras, K. Pericytes promote endothelial cell survival through induction of autocrine VEGF-A signaling and Bcl-w expression. Blood, 2011, 118(10), 2906-2917.
[http://dx.doi.org/10.1182/blood-2011-01-331694] [PMID: 21778339]
[88]
Claesson-Welsh, L.; Welsh, M. VEGFA and tumour angiogenesis. J. Intern. Med., 2013, 273(2), 114-127.
[http://dx.doi.org/10.1111/joim.12019] [PMID: 23216836]
[89]
Huang, M.; Lin, Y.; Wang, C. New insights into antiangiogenic therapy resistance in cancer: Mechanisms and therapeutic aspects. Drug Resist. Updat., 2022, 64100849
[http://dx.doi.org/10.1016/j.drup.2022.100849] [PMID: 35842983]
[90]
Helfrich, I.; Scheffrahn, I.; Bartling, S. Resistance to antiangiogenic therapy is directed by vascular phenotype, vessel stabilization, and maturation in malignant melanoma. J. Exp. Med., 2010, 207(3), 491-503.
[http://dx.doi.org/10.1084/jem.20091846] [PMID: 20194633]
[91]
Cascone, T.; Herynk, M.H.; Xu, L. Upregulated stromal EGFR and vascular remodeling in mouse xenograft models of angiogenesis inhibitor-resistant human lung adenocarcinoma. J. Clin. Invest., 2011, 121(4), 1313-1328.
[http://dx.doi.org/10.1172/JCI42405] [PMID: 21436589]
[92]
Okamoto, S.; Nitta, M.; Maruyama, T. Bevacizumab changes vascular structure and modulates the expression of angiogenic factors in recurrent malignant gliomas. Brain Tumor Pathol., 2016, 33(2), 129-136.
[http://dx.doi.org/10.1007/s10014-016-0248-6] [PMID: 26826105]
[93]
Prete, A.; Lo, A.S.; Sadow, P.M. Pericytes elicit resistance to vemurafenib and sorafenib therapy in thyroid carcinoma via the TSP-1/TGFβ1 axis. Clin. Cancer Res., 2018, 24(23), 6078-6097.
[http://dx.doi.org/10.1158/1078-0432.CCR-18-0693] [PMID: 30076136]
[94]
Hainsworth, J.D.; Spigel, D.R.; Sosman, J.A. Treatment of advanced renal cell carcinoma with the combination bevacizumab/erlotinib/imatinib: A phase I/II trial. Clin. Genitourin. Cancer, 2007, 5(7), 427-432.
[http://dx.doi.org/10.3816/CGC.2007.n.030] [PMID: 18272024]
[95]
Niu, N.; Shen, X.; Wang, Z. Tumor cell-intrinsic epigenetic dysregulation shapes cancer-associated fibroblasts heterogeneity to metabolically support pancreatic cancer. Cancer Cell, 2024, 42(5), 869-884.e9.
[http://dx.doi.org/10.1016/j.ccell.2024.03.005] [PMID: 38579725]
[96]
Donahue, K.L.; Watkoske, H.R.; Kadiyala, P. Oncogenic KRAS-dependent stromal interleukin-33 directs the pancreatic microenvironment to promote tumor growth. Cancer Discov., 2024, 14(10), 1964-1989.
[http://dx.doi.org/10.1158/2159-8290.CD-24-0100] [PMID: 38958646]
[97]
Er, E.E.; Valiente, M.; Ganesh, K. Pericyte-like spreading by disseminated cancer cells activates YAP and MRTF for metastatic colonization. Nat. Cell Biol., 2018, 20(8), 966-978.
[http://dx.doi.org/10.1038/s41556-018-0138-8] [PMID: 30038252]
[98]
Shenoy, A.K.; Jin, Y.; Luo, H. Epithelial-to-mesenchymal transition confers pericyte properties on cancer cells. J. Clin. Invest., 2016, 126(11), 4174-4186.
[http://dx.doi.org/10.1172/JCI86623] [PMID: 27721239]
[99]
Lu, J.; Shenoy, A. Epithelial-to-pericyte transition in cancer. Cancers, 2017, 9(7), 77.
[http://dx.doi.org/10.3390/cancers9070077] [PMID: 28677655]
[100]
Wirsik, N.M.; Ehlers, J.; Mäder, L. TGF‐β activates pericytes via induction of the epithelial‐to‐mesenchymal transition protein SLUG in glioblastoma. Neuropathol. Appl. Neurobiol., 2021, 47(6), 768-780.
[http://dx.doi.org/10.1111/nan.12714] [PMID: 33780024]
[101]
James, A.W.; Hindle, P.; Murray, I.R. Pericytes for the treatment of orthopedic conditions. Pharmacol. Ther., 2017, 171, 93-103.
[http://dx.doi.org/10.1016/j.pharmthera.2016.08.003] [PMID: 27510330]
[102]
Xu, C.; Hong, Q.; Zhuang, K. Regulation of pericyte metabolic reprogramming restricts the AKI to CKD transition. Metabolism, 2023, 145155592
[http://dx.doi.org/10.1016/j.metabol.2023.155592] [PMID: 37230215]
[103]
Biffi, G.; Tuveson, D.A. Diversity and biology of cancer-associated fibroblasts. Physiol. Rev., 2021, 101(1), 147-176.
[http://dx.doi.org/10.1152/physrev.00048.2019] [PMID: 32466724]
[104]
Leask, A. Potential therapeutic targets for cardiac fibrosis: TGFbeta, angiotensin, endothelin, CCN2, and PDGF, partners in fibroblast activation. Circ. Res., 2010, 106(11), 1675-1680.
[http://dx.doi.org/10.1161/CIRCRESAHA.110.217737] [PMID: 20538689]
[105]
Garon, E.B.; Rizvi, N.A.; Hui, R. Pembrolizumab for the treatment of non-small-cell lung cancer. N. Engl. J. Med., 2015, 372(21), 2018-2028.
[http://dx.doi.org/10.1056/NEJMoa1501824] [PMID: 25891174]
[106]
Gandhi, L.; Rodríguez-Abreu, D.; Gadgeel, S. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N. Engl. J. Med., 2018, 378(22), 2078-2092.
[http://dx.doi.org/10.1056/NEJMoa1801005] [PMID: 29658856]
[107]
Hamid, O.; Robert, C.; Daud, A. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N. Engl. J. Med., 2013, 369(2), 134-144.
[http://dx.doi.org/10.1056/NEJMoa1305133] [PMID: 23724846]
[108]
Larkin, J.; Chiarion-Sileni, V.; Gonzalez, R. Five-year survival with combined nivolumab and ipilimumab in advanced melanoma. N. Engl. J. Med., 2019, 381(16), 1535-1546.
[http://dx.doi.org/10.1056/NEJMoa1910836] [PMID: 31562797]
[109]
Pan, Y.; Yu, Y.; Wang, X.; Zhang, T. Tumor-associated macrophages in tumor immunity. Front. Immunol., 2020, 11583084
[http://dx.doi.org/10.3389/fimmu.2020.583084] [PMID: 33365025]
[110]
Wu, K.; Lin, K.; Li, X. Redefining tumor-associated macrophage subpopulations and functions in the tumor microenvironment. Front. Immunol., 2020, 11, 1731.
[http://dx.doi.org/10.3389/fimmu.2020.01731] [PMID: 32849616]
[111]
Yang, Y.; Andersson, P.; Hosaka, K. The PDGF-BB-SOX7 axis-modulated IL-33 in pericytes and stromal cells promotes metastasis through tumour-associated macrophages. Nat. Commun., 2016, 7(1), 11385.
[http://dx.doi.org/10.1038/ncomms11385] [PMID: 27150562]
[112]
Motegi, S.; Leitner, W.W.; Lu, M. Pericyte-derived MFG-E8 regulates pathologic angiogenesis. Arterioscler. Thromb. Vasc. Biol., 2011, 31(9), 2024-2034.
[http://dx.doi.org/10.1161/ATVBAHA.111.232587] [PMID: 21737783]
[113]
Yamada, K.; Uchiyama, A.; Uehara, A. MFG-E8 drives melanoma growth by stimulating mesenchymal stromal cell-induced angiogenesis and M2 polarization of tumor-associated macrophages. Cancer Res., 2016, 76(14), 4283-4292.
[http://dx.doi.org/10.1158/0008-5472.CAN-15-2812] [PMID: 27197197]
[114]
Wu, Z.; Thierry, K.; Bachy, S. Pericyte stem cells induce Ly6G+ cell accumulation and immunotherapy resistance in pancreatic cancer. EMBO Rep., 2023, 24(4)e56524
[http://dx.doi.org/10.15252/embr.202256524] [PMID: 36802267]
[115]
Zhu, C.; Chrifi, I.; Mustafa, D. CECR1-mediated cross talk between macrophages and vascular mural cells promotes neovascularization in malignant glioma. Oncogene, 2017, 36(38), 5356-5368.
[http://dx.doi.org/10.1038/onc.2017.145] [PMID: 28534507]
[116]
Bose, A.; Barik, S.; Banerjee, S. Tumor-derived vascular pericytes anergize Th cells. J. Immunol., 2013, 191(2), 971-981.
[http://dx.doi.org/10.4049/jimmunol.1300280] [PMID: 23785117]
[117]
Ochs, K.; Sahm, F.; Opitz, C.A. Immature mesenchymal stem cell-like pericytes as mediators of immunosuppression in human malignant glioma. J. Neuroimmunol., 2013, 265(1-2), 106-116.
[http://dx.doi.org/10.1016/j.jneuroim.2013.09.011] [PMID: 24090655]
[118]
Valdor, R.; García-Bernal, D.; Riquelme, D. Glioblastoma ablates pericytes antitumor immune function through aberrant up-regulation of chaperone-mediated autophagy. Proc. Natl. Acad. Sci. USA, 2019, 116(41), 20655-20665.
[http://dx.doi.org/10.1073/pnas.1903542116] [PMID: 31548426]
[119]
Galassi, C.; Chan, T.A.; Vitale, I.; Galluzzi, L. The hallmarks of cancer immune evasion. Cancer Cell, 2024, 42(11), 1825-1863.
[http://dx.doi.org/10.1016/j.ccell.2024.09.010] [PMID: 39393356]
[120]
Ruan, J.; Luo, M.; Wang, C. Imatinib disrupts lymphoma angiogenesis by targeting vascular pericytes. Blood, 2013, 121(26), 5192-5202.
[http://dx.doi.org/10.1182/blood-2013-03-490763] [PMID: 23632889]
[121]
Thijssen, V.L.J.L.; Paulis, Y.W.J.; Nowak-Sliwinska, P. Targeting PDGF‐mediated recruitment of pericytes blocks vascular mimicry and tumor growth. J. Pathol., 2018, 246(4), 447-458.
[http://dx.doi.org/10.1002/path.5152] [PMID: 30101525]
[122]
Cooke, V.G.; LeBleu, V.S.; Keskin, D. Pericyte depletion results in hypoxia-associated epithelial-to-mesenchymal transition and metastasis mediated by met signaling pathway. Cancer Cell, 2012, 21(1), 66-81.
[http://dx.doi.org/10.1016/j.ccr.2011.11.024] [PMID: 22264789]
[123]
Keskin, D.; Kim, J.; Cooke, V.G. Targeting vascular pericytes in hypoxic tumors increases lung metastasis via angiopoietin-2. Cell Rep., 2015, 10(7), 1066-1081.
[http://dx.doi.org/10.1016/j.celrep.2015.01.035] [PMID: 25704811]
[124]
Han, B.; Li, K.; Wang, Q. Effect of anlotinib as a third-line or further treatment on overall survival of patients with advanced non-small cell lung cancer. JAMA Oncol., 2018, 4(11), 1569-1575.
[http://dx.doi.org/10.1001/jamaoncol.2018.3039] [PMID: 30098152]
[125]
Kang, Y.K.; Ryu, M.H.; Yoo, C. Resumption of imatinib to control metastatic or unresectable gastrointestinal stromal tumours after failure of imatinib and sunitinib (RIGHT): A randomised, placebo-controlled, phase 3 trial. Lancet Oncol., 2013, 14(12), 1175-1182.
[http://dx.doi.org/10.1016/S1470-2045(13)70453-4] [PMID: 24140183]
[126]
Schlumberger, M.; Tahara, M.; Wirth, L.J. Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N. Engl. J. Med., 2015, 372(7), 621-630.
[http://dx.doi.org/10.1056/NEJMoa1406470] [PMID: 25671254]
[127]
Sternberg, C.N.; Davis, I.D.; Mardiak, J. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J. Clin. Oncol., 2010, 28(6), 1061-1068.
[http://dx.doi.org/10.1200/JCO.2009.23.9764] [PMID: 20100962]
[128]
Grothey, A.; Cutsem, E.V.; Sobrero, A. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): An international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet, 2013, 381(9863), 303-312.
[http://dx.doi.org/10.1016/S0140-6736(12)61900-X] [PMID: 23177514]
[129]
Llovet, J.M.; Ricci, S.; Mazzaferro, V. Sorafenib in advanced hepatocellular carcinoma. N. Engl. J. Med., 2008, 359(4), 378-390.
[http://dx.doi.org/10.1056/NEJMoa0708857] [PMID: 18650514]
[130]
Brose, M.S.; Nutting, C.M.; Jarzab, B. Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: A randomised, double-blind, phase 3 trial. Lancet, 2014, 384(9940), 319-328.
[http://dx.doi.org/10.1016/S0140-6736(14)60421-9] [PMID: 24768112]
[131]
Ravaud, A.; Motzer, R.J.; Pandha, H.S. Adjuvant sunitinib in high-risk renal-cell carcinoma after Nephrectomy. N. Engl. J. Med., 2016, 375(23), 2246-2254.
[http://dx.doi.org/10.1056/NEJMoa1611406] [PMID: 27718781]
[132]
Haas, N.B.; Manola, J.; Uzzo, R.G. Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): A double-blind, placebo-controlled, randomised, phase 3 trial. Lancet, 2016, 387(10032), 2008-2016.
[http://dx.doi.org/10.1016/S0140-6736(16)00559-6] [PMID: 26969090]
[133]
Wu, Y.; Ma, W.; Liu, W.; Zhang, S. Lactate: A pearl dropped in the ocean—an overlooked signal molecule in physiology and pathology. Cell Biol. Int., 2023, 47(2), 295-307.
[http://dx.doi.org/10.1002/cbin.11975] [PMID: 36511218]

Rights & Permissions Print Cite
Article Metrics
Pdf icon 28
Html icon 1
Find your institution